BrightGene Bio Medical Technology C (688166) - Total Assets
Based on the latest financial reports, BrightGene Bio Medical Technology C (688166) holds total assets worth CN¥5.38 Billion CNY (≈ $787.82 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BrightGene Bio Medical Technology C - Total Assets Trend (2016–2024)
This chart illustrates how BrightGene Bio Medical Technology C's total assets have evolved over time, based on quarterly financial data. Also see BrightGene Bio Medical Technology C market capitalisation for the company's overall valuation and market capitalisation.
BrightGene Bio Medical Technology C - Asset Composition Analysis
Current Asset Composition (December 2024)
BrightGene Bio Medical Technology C's total assets of CN¥5.38 Billion consist of 31.8% current assets and 68.2% non-current assets. Review 688166 total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 14.8% |
| Accounts Receivable | CN¥327.78 Million | 6.4% |
| Inventory | CN¥364.61 Million | 7.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥103.82 Million | 2.0% |
| Goodwill | CN¥3.12 Million | 0.1% |
Asset Composition Trend (2016–2024)
This chart illustrates how BrightGene Bio Medical Technology C's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See BrightGene Bio Medical Technology C stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BrightGene Bio Medical Technology C's current assets represent 31.8% of total assets in 2024, a decrease from 54.4% in 2016.
- Cash Position: Cash and equivalents constituted 14.8% of total assets in 2024, up from 10.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, unchanged from 2.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 7.1% of total assets.
BrightGene Bio Medical Technology C Competitors by Total Assets
Key competitors of BrightGene Bio Medical Technology C based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Abivax SA
PA:ABVX
|
France | €547.14 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥729.16 Million |
|
Pulike Biological Engineering
SHG:603566
|
China | CN¥3.09 Billion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $423.10 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
BrightGene Bio Medical Technology C - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.33 | 1.72 | 4.14 |
| Quick Ratio | 1.01 | 1.39 | 3.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥386.93 Million | CN¥724.85 Million | CN¥803.42 Million |
BrightGene Bio Medical Technology C - Advanced Valuation Insights
This section examines the relationship between BrightGene Bio Medical Technology C's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.84 |
| Latest Market Cap to Assets Ratio | 0.44 |
| Asset Growth Rate (YoY) | 2.6% |
| Total Assets | CN¥5.16 Billion |
| Market Capitalization | $2.28 Billion USD |
Valuation Analysis
Below Book Valuation: The market values BrightGene Bio Medical Technology C's assets below their book value (0.44x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: BrightGene Bio Medical Technology C's assets grew by 2.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for BrightGene Bio Medical Technology C (2016–2024)
The table below shows the annual total assets of BrightGene Bio Medical Technology C from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.16 Billion ≈ $755.71 Million |
+2.63% |
| 2023-12-31 | CN¥5.03 Billion ≈ $736.32 Million |
+7.95% |
| 2022-12-31 | CN¥4.66 Billion ≈ $682.09 Million |
+56.97% |
| 2021-12-31 | CN¥2.97 Billion ≈ $434.55 Million |
+62.47% |
| 2020-12-31 | CN¥1.83 Billion ≈ $267.46 Million |
+28.60% |
| 2019-12-31 | CN¥1.42 Billion ≈ $207.98 Million |
+61.81% |
| 2018-12-31 | CN¥878.37 Million ≈ $128.53 Million |
+67.34% |
| 2017-12-31 | CN¥524.92 Million ≈ $76.81 Million |
+36.63% |
| 2016-12-31 | CN¥384.19 Million ≈ $56.22 Million |
-- |
About BrightGene Bio Medical Technology C
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also pr… Read more